IngredientsSynonyms for oligomeric proanthocyanidins include procyanidins, procyanidolic oligomers (PCOs), leucoanthocyanins, condensed tannins, and pycnogenols, although the latter term is no longer used. Proanthocyanidins, more technically oligomeric proanthocyanidins (OPCs), are classed within the broad group of naturally occurring antioxidant substances found in plants known as polyphenolic flavonoids.
Chemically, proanthocyanidins are a heterogeneous group of flavan-3-ol or flavan-3,4-diol oligomers present in various fruits and vegetables. They are oligomeric flavonoids. Many are oligomers of catechin and epicatechin and their gallic acid esters. Depending on the degree of polymerization, proanthocyanidins are primarily classified into two isoforms: oligomeric proanthocyanidin (OPC), which have 2–5 monomers, and polymeric proanthocyanidin (PPC), which possess more than 5 monomers.
OPCs are polymers comprising many different monomers, such as catechins and epicatechins. The monomers are usually linked to each other by two types of bonds: A-linkages (C–O–C) and B-linkages (C–C). The common connection method of natural OPCs is the B-type. Proanthocyanidins, including the lesser bioactive and bioavailable polymers (four or more catechins), represent a group of condensed flavan-3-ols, such as procyanidins, prodelphinidins, and propelargonidins.
Oligomeric proanthocyanidins (OPC) strictly refer to dimer and trimer polymerizations of catechins. While larger proanthocyanidins polymers are difficult to be absorbed by the body, shorter oligomers (dimers, trimers and tetramers) are often referred to as OPCs; this subset is extracted from grape seeds and purified specifically for oligomers.
OPCs are natural compounds derived from plants, notably found in grape seeds and the bark of French maritime pine. They can be found in many plants, most notably apples, maritime pine bark and that of most other pine species, cinnamon, aronia fruit, cocoa beans, grape seed, grape skin, and red wines of Vitis vinifera (the European wine grape). Bilberry, cranberry, black currant, green tea, black tea, and other plants also contain these flavonoids. Cocoa beans contain the highest concentrations.
The two most common commercial sources of proanthocyanidins are grape seeds (Vitis vinifera) and the French maritime pine (Pinus maritima, P. pinaster) of southern Europe. Pycnogenol® is the trade name for an OPC extract from the bark of the French maritime pine tree.
Vitis Vinifera (Grape) Seed Extract, as the trade name ActiVin, contains 54% dimeric, 13% trimeric, and 7% tetrameric oligomeric proanthocyanidins and a small amount of catechin derivatives, flavonoids, and other oligomeric proanthocyanidins.
In nature, proanthocyanidins serve among other chemical and induced defense mechanisms against plant pathogens and predators, such as occurs in strawberries.
OPCs are commercially available in several standardized forms. Common names for grape-seed-derived preparations include: grape seed, grape seed extract, muskat, oligomeric proanthocyanidin complexes (OPC), proanthocyanidin, and procyanidolic oligomers (PCO). Composition of commercial grape seed preparations is highly variable. As with pine bark extract, grape seed extract also contains OPCs; confusion has arisen when grape seed extract was marketed as containing "Pycnogenol," the proprietary name used for OPCs specifically derived from pine bark.
Today, dietary intake of OPCs varies from tens to hundreds of milligrams per day, depending on geographical and seasonal dietary differences. Both extracts are sold as capsules, tablets, and liquid tinctures, and are also incorporated into topical cosmetic formulations.
Proanthocyanidins were discovered in 1947 by Jacques Masquelier, who developed and patented techniques for the extraction of oligomeric proanthocyanidins from pine bark and grape seeds. Albert Szent-Györgyi, a 1937 Nobel Prize winner, had earlier discovered flavonoids while working on the segregation of vitamin C, terming them "vitamin P." Professor Jacques Masquelier subsequently postulated that because pine bark exhibited ascorbate-like effects, it must contain vitamin C along with flavonoids, which he designated as "pycnogenols," a term no longer used by the scientific community except as a trademark for proanthocyanidins extracted from French maritime pine bark.
Masquelier improved and patented a technique to extract oligomeric grape seed proanthocyanidins in 1947, and observed that the bioflavonoids derived from grape seeds appeared to be superior in both concentration and antioxidant effect to those from pine bark.
Jacques Masquelier of the University of Bordeaux, France, first studied OPCs in depth after reading of explorer Jacques Cartier's 1534 expedition up the St. Lawrence River, in which Cartier's crew, trapped in ice flows and dying of scurvy, survived after Native Americans gave them a tea brewed from the bark and needles of the native pine. Masquelier later postulated that the pine constituents contained vitamin C and flavonoids that aided in the crew's recovery.
Proanthocyanidins are found in most plants and are widely distributed in fruits, grains, and vegetables. The presence of endogenous proanthocyanidins in plants also serves as a means of defense against external disturbances because the unique smell and special chemical structure of proanthocyanidins can repel insects; they also help the plant resist various stresses encountered during growth.
The use of grape seed preparations has roots in European viticulture traditions; grape pomace (the residue after wine pressing, including seeds and skins) has long been incorporated in folk applications for vascular and skin conditions across Mediterranean cultures. Pine bark preparations from various Pinus species appear in historical accounts of traditional use in indigenous North American medicine, and decoctions of astringent barks rich in tannins and proanthocyanidins were employed in many traditional pharmacopoeias for wound care, diarrhea, and fever. Proanthocyanidins were first formally discovered by Jacques Masquelier, a French researcher who developed techniques for their extraction and assigned them "vitamin P" from Rusznyak in the late 1940s.
Proanthocyanidins comprise epicatechin, catechin, epigallocatechin or gallocatechin subunits connected by C4–C6 and C4–C8 bonds. Grape seed extract contains OPCs made up of dimers or trimers of (+)-catechin and (−)-epicatechin. The most commercially significant individual oligomers include procyanidins B1, B2, B3, and B4 (dimers) and procyanidin C1 (a trimer). B-type proanthocyanidins are linked by C4→C8 and/or C4→C6 bonds.
Numerous studies have shown that compared to high polymeric procyanidins, OPCs exhibit antioxidant properties due to the presence of multiple hydroxyl groups. The gallic acid ester forms (e.g., epicatechin-3-O-gallate) are also present in significant quantities in grape seed extracts, contributing to the overall polyphenolic profile.
The major constituents in grape seed and pine bark extracts are proanthocyanidins. The GPC molecular weight (MW) distribution indicated components ranging from approximately 162 to approximately 5,500 MW, with pine bark extracts showing less than 1,180 MW and grape seed approximately 1,180 to approximately 5,000 MW. Pine bark extracts (Pycnogenol®) contain, in addition to OPCs, phenolic acids such as ferulic acid, caffeic acid, and taxifolin, as well as organic acids including coumaric and vanillic acids.
OPCs exhibit antioxidant properties due to the presence of multiple hydroxyl groups. They have anti-inflammatory, anti-aging, cardiovascular disease prevention, and antineoplastic functions. They are considered non-toxic and natural antioxidants of plant origin that scavenge free radicals from the human body.
As investigated in several in vitro, in vivo, and in clinical studies, Pycnogenol® French maritime pine bark extract showed antioxidative effects, anti-inflammatory abilities, beneficial effects on endothelial function, and reinforcing effects on the extracellular matrix.
OPC treatment significantly reduced the mRNA and protein of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), as well as the inflammation cytokines interleukin (IL)-6, IL-1β, and tumor necrosis factor-α (TNF-α). Moreover, OPCs downregulated LPS-induced phosphorylation of p65 and inhibitor of NF-κB (IκB) in the NF-κB signaling pathway, and they inhibited p65 translocation from the cytoplasm to the nucleus. Additionally, OPCs decreased phosphorylation of p38, extracellular signal-regulated kinase, and c-jun NH2-terminal kinase in the MAPK signaling pathway.
In conclusion, the anti-inflammatory and antioxidant activities of OPCs involve NF-κB and MAPK signaling pathways, thus inhibiting expression of pro-inflammatory factors and oxidation indicators. These findings come from cell-culture models and require corroboration in human systems.
Proanthocyanidins improve vascular endothelial function, decrease vascular permeability, and prevent vascular damage by inhibiting release of inflammatory factors, eliminating ROS, and reducing the production of immunoglobulins and deposition of immune complexes.
Pycnogenol® (PYC) antagonizes the vasoconstriction caused by epinephrine and norepinephrine by increasing the activity of endothelial nitric oxide synthase. Dilation of the small blood vessels has been observed in patients with cardiovascular disease, whereas in smokers, PYC prevents smoking-induced platelet aggregation and reduces the concentration of thromboxane. The ability to inhibit angiotensin-converting enzyme is associated with a mild antihypertensive effect.
OPCs have been reported to demonstrate antioxidant, antibacterial, antiviral, anticarcinogenic, anti-inflammatory, anti-allergic, and vasodilatory actions. They can inhibit lipid peroxidation, platelet aggregation, and capillary hyperpermeability.
OPCs show anti-inflammatory effects by inhibiting nitric oxide and prostaglandin E2 production and suppressing iNOS expression. OPCs also inhibit cell migration and modulate proliferation of human umbilical vascular endothelial cells by inducing significant gene expression change.
OPCs interact with structural proteins of the extracellular matrix, including collagen and elastin, by binding to procollagen and inhibiting collagenase and elastase enzyme activity. In cell models, proanthocyanidins promote the synthesis of type I collagen in aging fibroblasts through the TGF-β1/Smads pathway and inhibit the degradation of collagen by regulating the MMPs/TIMPs system, thereby maintaining the stability of the extracellular matrix structure. These mechanisms are primarily established in preclinical systems.
Research suggests that proanthocyanidins (PACs), a component of cranberries, inhibit the adherence of p-fimbriated Escherichia coli on uroepithelial cells of the bladder, preventing the adherence of bacteria to the mucosal surface of the urinary tract and thereby inhibiting bacterial proliferation. Type A proanthocyanidins destroy only the bond of the pathogenic bacteria to the receptors without destroying the entire E. coli population, some strains of which are part of the beneficial microflora in the gut. Clinical studies show that only so-called A-type PACs in cranberries have this antiadhesive effect.
The bioavailability of proanthocyanidins is largely influenced by their degree of polymerization. The absorption rate of proanthocyanidin dimers is 5–10% of that of (−)-epicatechin. Trimers and tetramers had lower absorption rates than dimers.
Proanthocyanidins with a degree of polymerization over 4 (DP>4) are not absorbable because of their large molecular size and the gut barrier. Depolymerization of proanthocyanidins in the gastrointestinal tract was negligible. The majority of proanthocyanidins reaches the colon intact and is degraded into phenylvalerolactones and phenolic acids by colon microbiota. These microbial metabolites may contribute to the health-promoting properties of proanthocyanidins in vivo.
When oligomeric and polymeric PACs are orally ingested, a large portion of the PACs reach the colon, where a small portion is subjected to microbial degradation to phenolic acids and valerolactones, despite the possibility that slight depolymerization of PACs occurs in the stomach and small intestine. Valerolactones, as microbiota-generated catabolites of PACs, may contribute to some of the health benefits of orally ingested PACs.
The rest interact with gut microbiota, resulting in improved microbial diversity, which includes an increased amount of beneficial gut bacteria (e.g., Akkermansia muciniphila), which could ameliorate host metabolic functions, and a lowered ratio of Firmicutes/Bacteroidetes at the phylum level, which could mitigate obesity-related metabolic disorders.
Proanthocyanidin has low bioavailability, with 90% remaining unabsorbed from the intestines until metabolized by gut flora to the more bioavailable metabolites. This low direct bioavailability is a critical factor complicating interpretation of dose-response relationships in clinical studies.
This is among the best-supported clinical application areas for OPCs. A two-month, double-blind, placebo-controlled trial of forty people with chronic venous insufficiency found that 100 mg of pine bark OPCs three times daily significantly reduced edema, pain, and the sensation of leg heaviness.
A double-blind study of fifty people with varicose veins of the legs found that doses of 150 mg per day of grape seed OPCs were more effective in reducing symptoms and signs than the bioflavonoid diosmin. Similarly, a double-blind study of thirty-nine people found pine bark OPCs more effective than the herb horse chestnut.
A pilot study using objective imaging assessed OPCs in CVI: 4D flow MRI was used to assess changes in blood flow velocity. A total of 23 participants were selected, with 10 in the stocking treatment group and 13 in the stocking + GSPE treatment group. In the stocking treatment group, the Th-Plane peak velocity increased by 2.48 ± 5.05 cm/s (P = .16). In the stocking + GSPE treatment group, the Th-Plane peak velocity increased by 4.85 ± 5.57 cm/s (P < .001). This was a small pilot study and results require replication.
Through antioxidative, anti-inflammatory, endothelial, and extracellular matrix mechanisms, Pycnogenol® supplementation has been shown in RDP human clinical trials to beneficially affect chronic venous insufficiency.
Evidence assessment: Moderate strength for symptomatic improvement in CVI. Multiple small RCTs support benefit, but larger, independent multicenter trials are lacking.
A double-blind, placebo-controlled study of sixty-three postoperative breast cancer patients found that 600 mg of grape seed OPCs daily for six months reduced edema, pain, and peculiar sensations known as paresthesias.
Evidence assessment: Preliminary. A single relatively small RCT supports benefit in post-mastectomy edema; broader replication is needed.
The effects of Pycnogenol® on cardiovascular and endothelial health have been investigated more than any other health condition, with ten human clinical randomized double-blind placebo-controlled (RDP) studies.
A randomized, double-blind, placebo-controlled study examined grape seed OPCs in prehypertension: the study was conducted on 6 men and 24 women aged 40–64 years old, who were randomized to receive either low-dose (200 mg/day) or high-dose (400 mg/day) GSPE, or placebo, for 12 weeks. The mean systolic blood pressure in the high-dose group significantly decreased by 13 mmHg after 12 weeks (P = 0.028).
A registry study of grape seed proanthocyanidins evaluated two dosages (150 and 300 mg/day) in pre- and mild hypertension. After four months of treatment, a statistically significant, dose-dependent improvement in all endpoints was observed in the treatment groups compared to the control, with blood pressure normalizing in 93% of the higher dosage (300 mg) treatment group. This was an observational registry study rather than an RCT, limiting causal inference.
Clinical studies have shown that Pycnogenol® can reduce blood glucose levels in people with diabetes, blood pressure in mild to moderate hypertensive patients, and waist circumference, and can improve lipid profile, renal and endothelial functions in metabolic syndrome.
In 39 randomized double-blind, placebo-controlled human clinical trials including 2,009 subjects, Pycnogenol® French maritime pine bark extract supplementation for two weeks to six months has been shown to beneficially affect cardiovascular health, chronic venous insufficiency, cognition, joint health, skin health, eye health, women's health, respiratory health and allergies, oral health, and sports performance.
Evidence assessment: Moderate for blood pressure in prehypertension/mild hypertension and for endothelial function markers, particularly for Pycnogenol®. Effect sizes are modest and study populations tend to be small.
OPCs might marginally improve blood sugar control in people with diabetes, according to a double-blind study of seventy-seven people with type 2 diabetes.
Procyanidins, recognized for their strong antioxidant, anti-inflammatory, and anti-hyperglycemic properties, play a crucial role in reducing oxidative stress and enhancing endothelial function. Research elucidates the molecular mechanisms by which procyanidins improve insulin sensitivity and endothelial health, thereby providing protection against the various complications of diabetes. The preponderance of evidence in this domain, however, derives from preclinical studies.
Grape seed extract may modestly reduce HbA1c and fasting blood glucose in some small clinical trials, but evidence is insufficient to recommend it as a treatment for type 2 diabetes. GSE is rich in OPCs with antioxidant and anti-inflammatory properties. Some small RCTs report modest reductions in HbA1c and fasting glucose with GSE, but study quality is generally low to moderate and sample sizes are small.
Evidence assessment: Preliminary and weak for glycemic control in humans. Small underpowered trials with mixed results; no regulatory body endorses OPCs for glycemic management.
Cranberries contain proanthocyanidins (PACs), which are stable phenolic compounds with anti-adhesion activity against Escherichia coli. There is still conflicting scientific data about the usefulness of cranberry products in preventing UTIs. Research has investigated whether the content of the main component, proanthocyanidins (PACs), in cranberries affects their ability to prevent UTIs.
A multicentre randomized clinical trial (RCT) in sexually active adult women showed that a daily dose of 36 mg PACs or more provided an optimal antibacterial effect in the urine. A Cochrane systematic review published in 2012 could not definitively conclude on the efficacy of cranberry products for the prevention of recurrent UTI, mainly because of a lack of adherence to the intake of cranberry supplements in juice form and because of varying PAC concentrations in the studies.
Clinical studies show that only so-called A-type PACs in cranberries have an antiadhesive effect—the B-type OPCs predominant in grape seed and pine bark extracts are structurally distinct and do not possess the same anti-adhesion mechanism.
Evidence assessment: Mixed for UTI prevention. A-type cranberry PACs have a plausible mechanism and moderate clinical support for recurrent UTI prevention; B-type OPCs from grape seed or pine bark are not established for this use.
An improvement in cognitive function has been observed in controlled animal experiments, and these findings support anecdotal reports of improvement in ADHD patients taking Pycnogenol® supplements. Some studies indicate that the brain's alpha, beta, and theta waves are positively affected by OPCs, strengthening the blood-brain barrier and allowing improved neurotransmitter activity, cognitive function, and blood flow.
Pycnogenol® supplementation has been shown in RDP human clinical trials to beneficially affect cognition.
Evidence assessment: Preliminary. Individual RCTs are small and focused primarily on pine bark extract rather than other OPC sources. Evidence for ADHD is largely anecdotal or from small uncontrolled studies.
Two small, double-blind pilot studies suggest that OPCs from pine bark might help reduce asthma symptoms. OPCs are also often recommended for allergies, but an eight-week double-blind trial of forty-nine individuals found no benefit with grape seed extract. On a slightly more positive note, a preliminary trial involving thirty-nine people with seasonal allergies found that those who took OPCs at least five weeks before the start of the season experienced more symptom relief than the control group.
Evidence assessment: Weak. Studies are very small and inconsistent; no reliable clinical guidance can be based on these results.
Some evidence suggests that OPCs protect and strengthen collagen and elastin. Theoretically, this could mean that OPCs are helpful for aging skin, and they are widely sold for this purpose, but there is no direct clinical evidence that the herbs work.
At the preclinical level, proanthocyanidins could enhance the activities of superoxide dismutase and glutathione, effectively remove excess ROS, and significantly improve cell morphology and viability caused by excessive ROS in skin cells. In addition, proanthocyanidins promote the synthesis of type I collagen in aging fibroblasts through the TGF-β1/Smads pathway and inhibit the degradation of collagen by regulating the MMPs/TIMPs system, thereby maintaining the stability of the extracellular matrix structure. These effects are from cell culture models.
Pycnogenol® supplementation has been shown in RDP human clinical trials to beneficially affect skin health. Individual trials are generally small and short in duration.
Evidence assessment: Preliminary. Mechanistic cell-culture data are compelling; controlled human clinical evidence is limited in scale and scope.
Hemorrhoids are varicose veins in and around the anus. Since OPCs are used to treat varicose veins, it is thought that this substance would also be helpful for hemorrhoids. A randomized trial involving eighty-four people with hemorrhoids found that both the oral and topical forms of Pycnogenol® eased symptoms, including bleeding.
Evidence assessment: Preliminary. Single randomized trial; requires replication.
The smaller oligomeric subset of proanthocyanidins (OPCs) appears to have potent anti-tumorigenic properties, but the underlying mechanisms for their effectiveness remain unclear. In vitro, in vivo, and patient-derived organoid approaches have been utilized to systematically investigate the chemoprotective role of OPCs in colorectal cancer. OPCs exerted anti-tumorigenic effects through inhibition of cellular proliferation, and induced apoptosis and cell cycle arrest.
Proanthocyanidins tested on HeLa and SiHa cells via MTT assay exerted oxidative stress and mitochondrial damage, triggering apoptosis. However, this cancer cell inhibitory effect could be a case of osmotic alterations. The lack of immune surveillance in the in vitro test medium could have led to the death of the cancer cells, which is not likely in a cancerous body.
Evidence assessment: Preclinical only. All notable anti-cancer data derive from cell culture and animal models. No controlled human clinical trials establish OPCs as cancer-preventive or cancer-therapeutic agents.
Clinical trials and cohort studies have found that proanthocyanidins contribute to the improvement of menopausal symptoms, renal function, urinary tract infection, and skin damage in middle-aged and elderly women, as well as the prevention of cardiovascular disease, hypertension, obesity, cancer, and osteoporosis. In a randomized, double-blind, placebo-controlled study in Japanese women aged 40 to 60 years who received grape seed proanthocyanidins for 8 weeks, researchers evaluated the effect on menopausal symptoms.
Pycnogenol® relieves premenstrual symptoms, including abdominal pain, and this action may be associated with the spasmolytic action of some phenolic acids.
Evidence assessment: Preliminary to moderate. Small RCTs in defined populations provide supportive signals; larger confirmatory trials are needed.
OPC dosages vary considerably across studies depending on the source (grape seed vs. pine bark), the standardization of the extract, and the clinical target.
Clinical trials have generally reported that grape seed extract is well tolerated. No human toxicity has been reported for grape seed. No evidence of acute oral toxicity was found at dosages of 2 and 4 g/kg, and no evidence of mutagenicity was found. Administration of GSE as a dietary admixture at levels of 0.02, 0.2, and 2% (w/w) to rats for 90 days did not induce noticeable signs of toxicity.
The no-observed-adverse-effect level (NOAEL) of GSE in the subchronic toxicity study was 2% in the diet, equal to 1,410 mg/kg body weight/day in males and 1,501 mg/kg body weight/day in females.
Health Canada's safety assessment noted: the NOAEL of 1,788 mg GSE/kg body weight per day was used to establish safety levels, equivalent to 1,462 mg/kg bw per day of proanthocyanidins (based on 81.78% total proanthocyanidin content of the GSE test article).
There is evidence that polyphenols, which include proanthocyanidins, can bind iron, consequently inhibiting iron absorption; however, polyphenols must be ingested together with iron in order to inhibit its digestion, and the presence of ascorbic acid has been shown to reverse the inhibitory effects. Clinical trials indicate that doses of GSE up to 4.5 g per day in women (for 4 weeks) did not affect iron bioavailability or serum ferritin levels. Further, GSE supplementation up to 1.5 g per day in healthy adults (for 4 weeks) showed no significant changes in serum iron levels.
GSE has antiplatelet properties and may interact with anticoagulants (warfarin, DOACs) and antiplatelet drugs, increasing bleeding risk. GSE affects platelet function (for example, increases clotting time) in vitro; however, the available animal and clinical studies provide only minimal evidence that these effects could occur in vivo. The limited bioavailability of GSE constituents may limit their potential for effects on platelet function in vivo.
There is a theoretical risk of hypoglycemia when GSE is combined with insulin or sulphonylureas such as gliclazide.
CYP-450 enzyme-mediated herbal drug interactions are possible with grape seed extract; caution should be exercised. Grape seed may increase the serum concentration of dextromethorphan, although no action is considered necessary in most cases.
Grape seed is contraindicated in individuals with known hypersensitivity to grape products. Information regarding safety and efficacy in pregnancy and lactation is lacking.
Bioavailability of OPCs differs between individuals and formulations, complicating dose-response interpretation. Confounding factors such as diet, physical activity, and concurrent medication use are not always adequately controlled in clinical trials.
Pine bark extract demonstrates antioxidant and anti-inflammatory actions and has been studied for a wide range of clinical conditions, including asthma, attention-deficit/hyperactivity disorder (ADHD), chronic venous insufficiency, cardiovascular conditions, diabetes, and erectile dysfunction. However, many clinical trials are methodologically weak, making it difficult to support the use of pine bark extract for any condition.
Large, quality clinical trials are lacking to recommend use for any single indication. While some small trials indicate potential benefits, larger-scale and more rigorous studies are needed to establish effectiveness across these conditions.
Health conditions that Oligomeric proanthocyanidins may help support.
Oligomeric proanthocyanidins (OPCs) from grape seed and pine bark inhibit ACE, enhance endothelial NO production, reduce LDL oxidation, and improve arterial flexibility. Meta-analyses of RCTs show OPCs from grape seed extract reduce SBP by ~6 mmHg and DBP by ~3 mmHg. Life Extension's cardiovascular protocol listed proanthocyanidins from grape seeds among anti-atherogenic compounds improving endothelial function.
Oligomeric proanthocyanidins (OPCs) from grape seed and pine bark reduce LDL oxidation and demonstrate modest LDL-C-lowering effects in some clinical trials. Evidence is more limited compared to phytosterols or berberine but is present in peer-reviewed lipid literature.
Oligomeric proanthocyanidins (OPCs) are the condensed, bioavailable fraction of proanthocyanidins with documented anti-aging effects including collagen protection, vascular health support, and antioxidant activity exceeding vitamins C and E. Pycnogenol (pine bark OPCs) and grape seed OPC extracts have robust clinical trial evidence for cardiovascular and skin aging outcomes.
Oligomeric proanthocyanidins (OPCs), found in grape seed and pine bark, inhibit tyrosinase and scavenge UV-induced free radicals, reducing hyperpigmentation. They are used both orally (for prevention of postprocedural PIH) and topically, and are cited among evidence-based natural depigmenting agents in dermatological reviews.
Oligomeric proanthocyanidins (OPCs), particularly from grape seed, demonstrated significant improvement in lymphatic drainage in a 2025 Frontiers in Oncology preclinical study using near-infrared fluorescence lymphangiography in a rat secondary lymphedema model. OPCs stabilize capillary walls, reduce vascular permeability, and provide anti-inflammatory effects directly relevant to lymphedema. They are classified as venoactive compounds for lymphatic and venous insufficiency in pharmacological reviews.
Oligomeric proanthocyanidins (OPCs), found in pine bark (Pycnogenol) and grape seed extract, are well-studied for chronic venous disease including spider veins. They strengthen capillary walls, reduce vascular permeability, and have antioxidant and anti-inflammatory effects. Clinical studies show reduction in CVI symptoms and, specifically for Pycnogenol, reduction in spider vein appearance and clustering.
Oligomeric proanthocyanidins (OPCs) from grape seed and pine bark are the best-documented class of plant bioflavonoids for varicose veins and CVI. Placebo-controlled double-blind studies involving approximately 400 participants found OPCs provide significant benefits for varicose vein symptoms. OPCs improve collagen integrity, reduce capillary leakage, and control inflammation. ConsumerLab notes several small studies showing grape seed OPCs reduce symptoms of venous insufficiency.
Oligomeric proanthocyanidins (OPCs) from grape seed and pine bark are listed by EBSCO Research Starters as proposed natural treatments for hemorrhoids. A 2021 PMC retrospective study incorporating Vitis vinifera extract (OPCs) in a multi-ingredient phlebotonic achieved 89.8% hemorrhoid grade reduction in grade II–III patients. Mechanistic evidence supports capillary-stabilizing and anti-inflammatory effects relevant to hemorrhoidal disease.
Oligomeric proanthocyanidins (OPCs), found in grape seed extract and pine bark (Pycnogenol), are potent flavonoid antioxidants with vasodilatory and anti-inflammatory properties. EBSCO Research Starters cite 'weak but interesting evidence' that OPCs, like bilberry, may prevent or treat macular degeneration due to their flavonoid content and vascular protective effects. Preclinical studies show grape seed extract may protect against AMD and neurodegenerative processes.
Oligomeric proanthocyanidins (OPCs), found in grape seed and pine bark, are proposed natural treatments for nosebleeds. They inhibit collagen-degrading enzymes and reduce capillary fragility; one small, poorly-designed double-blind trial found OPCs superior to placebo for capillary fragility, though nosebleeds were not directly assessed.
Body systems that Oligomeric proanthocyanidins may help support.
Go back